CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
| Brand Name | Lynparza |
|---|---|
| Generic Name | Olaparib |
| Tumour Type | Breast |
| Indication | Treatment of adult patients with deleterious or suspected deleterious germline BRCAmutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. |
| Review Status | Not Filed |
| Clarification | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer. |
| Pre Noc Submission | |
| NOC Date | |
| Manufacturer | AstraZeneca Canada |
| Submission Date (Target Date) | |
| Submission Type | Non-Submission |
| Prioritization Requested | |
| Stakeholder Input Deadline (target date based on target submission date) ‡ | |
| Check-point meeting (target date) | |
| pERC Meeting (target date) | |
| Initial Recommendation Issued (target date) | |
| Feedback Deadline (target date) ‡ | |
| pERC Reconsideration Meeting (target date) | |
| Final Recommendation Issued (target date) | |
| Notification to Implement Issued |
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.